Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients

Inclusion Criteria: * Between the ages of 18 and 80 * ACS (STEMI or NSTE-ACS) * Patients to receive standardised drug therapy * Able and willing to provide informed consent Exclusion Criteria: * Any contraindication to colchicine or known intolerance to colchicine * Has been using colchicine for a prolonged period of time for other medical conditions * Women of childbearing age who are pregnant, breastfeeding or not using effective contraception * Coronary artery bypass grafting within the last 3 years or planned * Severe hepatic impairment: elevated serum alanine aminotransferase and/or aminotransferase (ALT) and/or aminotransferase (AST) levels of up to three times the upper limit of normal * Severe renal impairment: eGFR \<30mL/min/1.73m2 * Thrombocytopenia (platelet count less than 100\*10⁹/L) * Active diarrhoea * Infectious diseases: presence of uncontrollable infectious diseases * Immune-related diseases: known immune diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumours, etc. * Strong CYP3A4 or P glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) are already in use and no alternative medications can be administered * Planning to use systemic anti-inflammatory therapies such as NSAIDs, hormones, immunomodulators and chemotherapeutic agents